Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva.

Human saliva is known to possess components that decrease the HIV-1 infectivity in vitro. The mechanism of how these components inhibit the infectivity is still not clear on the molecular level. The purpose of this study was to discriminate between serous and mucous components with respect to inhibitory capacity and site of action. We have used total saliva and saliva from the major (sero)mucous glands: submandibular gland, sublingual glands, and glands in the palate, in comparison with the serous parotid glands. HIV-1 IIIB and primary variants were incubated with saliva, and inhibition of HIV-1-infection was determined by analysing the cytopathic effect on MT-2 cells. Mucous saliva, as well as serous saliva, contained high molecular weight components that reduced HIV-1-infectivity, at least partially by entrapment of the virus particles. Lower molecular weight components in all types of saliva possessed strong HIV-1 neutralizing capacity. Using pro-viral DNA synthesis by reverse transcription as a discrimination point in the replication cycle, the results indicated that part of the saliva samples acted before, but others after, this point. In conclusion, saliva inhibits HIV-1-infection by the action of high molecular weight components in combination with low molecular weight components from serous as well as mucous saliva, affecting different stages of the infection cycle.

[1]  A. Vissink,et al.  Human glandular salivas: their separate collection and analysis. , 1996, European journal of oral sciences.

[2]  E. Veerman,et al.  Immunochemical analysis of high molecular-weight human salivary mucins (MG1) using monoclonal antibodies. , 1991, Archives of oral biology.

[3]  M. Vafina,et al.  CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. , 1993, Molecular immunology.

[4]  B. Saltzman,et al.  Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis , 1986 .

[5]  E. Veerman,et al.  A Role for Lewis a antigens on salivary agglutinin in binding to Streptococcus mutans , 2004, Antonie van Leeuwenhoek.

[6]  E. Veerman,et al.  Detection and Quantification of MUC7 in Submandibular, Sublingual, Palatine, and Labial Saliva by Anti-peptide Antiserum , 1999, Journal of dental research.

[7]  R. Coutinho,et al.  HIV‐1 biological phenotype in long‐term infected individuals evaluated with an MT‐2 cocultivation assay , 1992, AIDS.

[8]  V. Hascall,et al.  Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. , 1993, AIDS research and human retroviruses.

[9]  F. Oppenheim,et al.  Human Salivary Mucin MG1 Selectively Forms Heterotypic Complexes with Amylase, Proline-rich Proteins, Statherin, and Histatins , 1997, Journal of dental research.

[10]  S. Baron,et al.  HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. , 1993, Journal of the American Dental Association.

[11]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[12]  M. Gonda,et al.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. , 1984, Science.

[13]  J. Guardiola,et al.  Interaction of seminal plasma proteins with cell surface antigens: presence of a CD4-binding glycoprotein in human seminal plasma. , 1991, Experimental cell research.

[14]  H. Friedman,et al.  Human submandibular saliva aggregates HIV. , 1993, AIDS research and human retroviruses.

[15]  H. Friedman,et al.  HIV in the oral cavity: virus, viral inhibitory activity, and antiviral antibodies: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[16]  S. Baron,et al.  Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. , 1999, Archives of internal medicine.

[17]  R. Silverstein,et al.  Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.

[18]  L. Epstein,et al.  Aggregation of human immunodeficiency virus type 1 by human salivary secretions. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[19]  L. Resnick,et al.  Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[20]  S. Wahl,et al.  Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. , 1997, Blood.

[21]  P. Fultz.  COMPONENTS OF SALIVA INACTIVATE HUMAN IMMUNODEFICIENCY VIRUS , 1986, The Lancet.

[22]  P. Fox,et al.  Saliva inhibits HIV-1 infectivity. , 1988, Journal of the American Dental Association.

[23]  D. Cooper,et al.  Patients infected with human immunodeficiency virus type 1 have low levels of virus in saliva even in the presence of periodontal disease. , 1993, The Journal of infectious diseases.

[24]  P. Fox,et al.  Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. , 1989, Journal of the American Dental Association.

[25]  D. van Strijp,et al.  Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplification assays. , 1993, AIDS research and human retroviruses.

[26]  H. Schuitemaker,et al.  Productive HIV‐1 infection of macrophages restricted to the cell fraction with proliferative capacity. , 1994, The EMBO journal.

[27]  N. Houdret,et al.  Strong ionic interactions between mucins and two basic proteins, mucus proteinase inhibitor and lysozyme, in human bronchial secretions. , 1992, The International journal of biochemistry.

[28]  E. Bloemena,et al.  A monoclonal antibody directed against high M(r) salivary mucins recognizes the SO3-3Gal beta 1-3GlcNAc moiety of sulfo-Lewis(a): a histochemical survey of human and rat tissue. , 1997, Glycobiology.

[29]  G. Cole,et al.  In vitro inhibition of HIV-1 infectivity by human salivas. , 1990, AIDS research and human retroviruses.

[30]  C. Barr,et al.  Recovery of infectious HIV-1 from whole saliva. , 1992, Journal of the American Dental Association.

[31]  D. Dripps,et al.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.

[32]  B. Prabhakar,et al.  Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. , 1991, AIDS research and human retroviruses.

[33]  M. Krieger,et al.  The other side of scavenger receptors: pattern recognition for host defense , 1997, Current opinion in lipidology.

[34]  D. Verwoerd,et al.  Distinct populations of high-M(r) mucins secreted by different human salivary glands discriminated by density-gradient electrophoresis. , 1995, The Biochemical journal.

[35]  N. Fujii,et al.  Defensins inhibit HIV replication in vitro. , 1993, AIDS.